ProMIS Neurosciences Inc. business relationships
Companies named in ProMIS Neurosciences Inc.’s 10-K filed 2026-03-25, and public companies whose annual reports name ProMIS Neurosciences Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 22 / 100 Top 2% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in ProMIS Neurosciences Inc.’s annual report 2
“...standing of Aβ biology described above, PMN310 was designed to be more selective for the toxic oligomer of amyloid than other anti-Aβ antibodies such as aducanumab from Biogen, lecanemab, co-developed by Eisai Co. and Biogen, donanemab from Lilly, ACU193 from Acumen and the Prothena PRX012 antibody.” SEC filing
“...standing of Aβ biology described above, PMN310 was designed to be more selective for the toxic oligomer of amyloid than other anti-Aβ antibodies such as aducanumab from Biogen, lecanemab, co-developed by Eisai Co. and Biogen, donanemab from Lilly, ACU193 from Acumen and the Prothena PRX012 antibody.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.